JP2016540195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540195A5 JP2016540195A5 JP2016523296A JP2016523296A JP2016540195A5 JP 2016540195 A5 JP2016540195 A5 JP 2016540195A5 JP 2016523296 A JP2016523296 A JP 2016523296A JP 2016523296 A JP2016523296 A JP 2016523296A JP 2016540195 A5 JP2016540195 A5 JP 2016540195A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- bcg
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 45
- 239000000203 mixture Substances 0.000 claims 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 108010075254 C-Peptide Proteins 0.000 claims 6
- 230000006378 damage Effects 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 229960002448 dasatinib Drugs 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 208000003532 hypothyroidism Diseases 0.000 claims 2
- 230000002989 hypothyroidism Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000013074 reference sample Substances 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 229920002148 Gellan gum Polymers 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010023379 Ketoacidosis Diseases 0.000 claims 1
- 208000007976 Ketosis Diseases 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 230000003683 cardiac damage Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019132484A JP6964632B2 (ja) | 2013-10-17 | 2019-07-18 | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
| JP2021170871A JP7909381B2 (ja) | 2013-10-17 | 2021-10-19 | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
| JP2023171996A JP2024001123A (ja) | 2013-10-17 | 2023-10-03 | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892140P | 2013-10-17 | 2013-10-17 | |
| US61/892,140 | 2013-10-17 | ||
| PCT/US2014/060908 WO2015057968A2 (en) | 2013-10-17 | 2014-10-16 | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132484A Division JP6964632B2 (ja) | 2013-10-17 | 2019-07-18 | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540195A JP2016540195A (ja) | 2016-12-22 |
| JP2016540195A5 true JP2016540195A5 (enExample) | 2017-11-24 |
| JP6560200B2 JP6560200B2 (ja) | 2019-08-14 |
Family
ID=52828855
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523296A Active JP6560200B2 (ja) | 2013-10-17 | 2014-10-16 | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
| JP2019132484A Active JP6964632B2 (ja) | 2013-10-17 | 2019-07-18 | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
| JP2023171996A Pending JP2024001123A (ja) | 2013-10-17 | 2023-10-03 | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132484A Active JP6964632B2 (ja) | 2013-10-17 | 2019-07-18 | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
| JP2023171996A Pending JP2024001123A (ja) | 2013-10-17 | 2023-10-03 | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12174188B2 (enExample) |
| JP (3) | JP6560200B2 (enExample) |
| KR (1) | KR102393711B1 (enExample) |
| CN (3) | CN111239415B (enExample) |
| WO (1) | WO2015057968A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2938339B1 (en) | 2012-12-27 | 2020-08-19 | Massachusetts Eye & Ear Infirmary | Treatment of rhinosinusitis with p-glycoprotein inhibitors |
| WO2015057968A2 (en) | 2013-10-17 | 2015-04-23 | The General Hospital Corporation | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same |
| WO2017059132A1 (en) * | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
| US11408900B2 (en) * | 2016-01-15 | 2022-08-09 | Massachusetts Eye And Ear Infirmary | Secreted P-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis |
| WO2018107701A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种新的降血糖和提高糖耐量的药物 |
| US11077179B2 (en) | 2017-08-10 | 2021-08-03 | Epicgenetics, Inc. | Method for treating fibromyalgia and chronic fatigue syndrome |
| CN109055523A (zh) * | 2018-07-16 | 2018-12-21 | 中山大学附属第三医院（中山大学肝脏病医院） | Tnfr2基因及其编码蛋白的应用 |
| KR102282342B1 (ko) * | 2018-11-20 | 2021-07-27 | 아주대학교산학협력단 | 베체트병 진단 또는 예후 예측용 바이오마커 조성물 |
| US12295933B2 (en) | 2019-03-25 | 2025-05-13 | Massachusetts Eye And Ear Infirmary | Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity |
| CN110804643B (zh) * | 2019-10-29 | 2022-06-21 | 同济大学 | 一种体外评价卡介苗对中性粒细胞活性影响的方法 |
| US20230284936A1 (en) * | 2020-07-10 | 2023-09-14 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Kits and methods for measuring insulin sensativity |
| CN112806322B (zh) * | 2021-03-22 | 2022-08-16 | 石河子大学 | 一种构建色素脱失模型的方法 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309418A (en) | 1980-03-25 | 1982-01-05 | Sloan-Kettering Research Institute For Cancer | Anti-tumor agent from human serum and process |
| SE8204382L (sv) | 1981-07-21 | 1983-01-22 | Hayashibara Biochem Lab | Sett att framstella malcellysfaktor och anvendning derav |
| US4457916A (en) | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5288852A (en) | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
| US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| DE3423234A1 (de) | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| US4677064A (en) | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| WO1986003751A2 (en) | 1984-12-21 | 1986-07-03 | Biogen N.V. | Purification, production and use of tumor necrosis factors |
| US4681760A (en) | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
| US5059530A (en) | 1985-09-30 | 1991-10-22 | Suntory Ltd. | Expression vector for human TNF |
| US5002876A (en) | 1986-09-22 | 1991-03-26 | Phillips Petroleum Company | Yeast production of human tumor necrosis factor |
| US4985241A (en) | 1986-11-21 | 1991-01-15 | Cetus Corporation | Therapeutic combination of free-radical scavenger and tumor necrosis factor |
| US4963354A (en) | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
| US5215743A (en) | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
| US5370870A (en) | 1989-10-06 | 1994-12-06 | Genentech, Inc. | Method for protection against reactive oxygen species |
| US5283058A (en) | 1990-08-30 | 1994-02-01 | The General Hospital Corporation | Methods for inhibiting rejection of transplanted tissue |
| US5593698A (en) | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| US5166142A (en) | 1991-06-10 | 1992-11-24 | University Of Rochester | Use of type ia antiarrhythmic agents to lower blood lipids |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6984380B1 (en) | 1991-08-02 | 2006-01-10 | Denise L. Faustman | Treatment of diseases involving faulty MHC class I antigen complex presentation |
| WO1993002690A1 (en) | 1991-08-02 | 1993-02-18 | The General Hospital Corporation | Diagnosis and treatment of autoimmune diseases |
| US5139481A (en) | 1991-08-07 | 1992-08-18 | The General Hospital Corporation | Treatment for type II diabetes |
| US5843425A (en) | 1992-02-19 | 1998-12-01 | The General Hospital Corporation | Transplantation and graft-versus-host-disease |
| ES2168273T3 (es) | 1992-04-23 | 2002-06-16 | Sloan Kettering Inst Cancer | Ligando para el receptor c-kit y metodos de uso del mismo. |
| WO1994009137A1 (en) | 1992-10-15 | 1994-04-28 | Genentech, Inc. | Antibodies against type 2 tumor necrosis factor receptor |
| US5843452A (en) | 1992-11-09 | 1998-12-01 | Pharmagenesis, Inc. | Immunotherapy composition and method |
| US5560908A (en) | 1993-01-22 | 1996-10-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Therapeutic agent for NIDDM |
| US5728385A (en) | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
| MX9700198A (es) * | 1994-07-08 | 1997-04-30 | Dartmouth College | Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1. |
| US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| WO1997008328A1 (en) | 1995-08-30 | 1997-03-06 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Selective elimination of t cells that recognize specific preselected targets |
| US6110206A (en) | 1995-09-15 | 2000-08-29 | Crosscart, Inc. | Anterior cruciate ligament xenografts |
| US5874306A (en) | 1996-12-12 | 1999-02-23 | The Regents Of The University Of California | Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells |
| AU6241698A (en) | 1997-01-21 | 1998-08-07 | Human Genome Sciences, Inc. | Tace-like and matrilysin-like polypeptides |
| US5837467A (en) * | 1997-01-21 | 1998-11-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for predicting the response to treatment with BCG of superficial bladder carcinoma |
| WO1999029343A1 (en) | 1997-12-09 | 1999-06-17 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
| US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6165737A (en) | 1998-04-16 | 2000-12-26 | The University Of Texas System Board Of Regents | DNA fragmentation factor involved in apoptosis |
| US6284879B1 (en) | 1998-04-16 | 2001-09-04 | The General Hospital Corporation | Transport associated protein splice variants |
| EP1077724A2 (en) | 1998-04-17 | 2001-02-28 | The University Of Vermont | Methods and products related to metabolic interactions in disease |
| WO1999059632A1 (en) | 1998-05-18 | 1999-11-25 | Applied Research Systems Ars Holding N.V. | Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions |
| US7485293B1 (en) | 1999-02-18 | 2009-02-03 | Faustman Denise L | Method for inhibiting transplant rejection |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| US20010046489A1 (en) | 1999-12-06 | 2001-11-29 | Habener Joel E. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| US6414218B1 (en) | 2000-01-18 | 2002-07-02 | The General Hospital Corporation | Mouse model for rheumatoid arthritis |
| US20020160502A1 (en) | 2000-09-26 | 2002-10-31 | Roger Williams Hospital | Recombinant BCG vaccines for the prevention and treatment of cancer |
| US20040031066A9 (en) | 2001-01-18 | 2004-02-12 | Faustman Denise L. | Mouse model for rheumatoid arthritis |
| US20020146753A1 (en) | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
| EP1424389A4 (en) | 2001-08-07 | 2004-08-25 | Kirin Brewery | METHOD FOR PRODUCING HEMATOPOETIC STEM CELLS |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| US7582313B2 (en) | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| AU2002952834A0 (en) * | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
| US20040229785A1 (en) * | 2002-11-15 | 2004-11-18 | Denise Faustman | Screening methods to identify treatments for autoimmune disease |
| CN1448724A (zh) * | 2003-05-13 | 2003-10-15 | 上海晶泰生物技术有限公司 | 1型糖尿病相关抗原抗体同时检测蛋白芯片 |
| US7510877B2 (en) | 2003-09-26 | 2009-03-31 | The Regents Of The University Of Michigan | Hematopoietic stem cell identification and isolation |
| WO2005040401A2 (en) | 2003-10-17 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp) |
| EP1733733A1 (en) | 2004-03-04 | 2006-12-20 | Takashi Kadowaki | Regulator for adiponectin receptor expression |
| US8563308B2 (en) | 2004-03-10 | 2013-10-22 | The Rockefeller University | Culture-expanded T suppressor cells and methods of use thereof |
| EP1750754A4 (en) | 2004-03-31 | 2010-09-22 | Centocor Ortho Biotech Inc | HUMAN GLP-1 MIMETIC BODIES, COMPOSITIONS, METHODS AND USES |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| WO2006004803A1 (en) | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
| WO2006006165A2 (en) | 2004-07-12 | 2006-01-19 | Yeda Research And Development Co. Ltd. | Use of erythropoietin for enhancing immune responses and for treatment of lymphoproliferative disorders |
| JP5704785B2 (ja) | 2004-07-19 | 2015-04-22 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 免疫抑制のためのｆｌｔ３阻害剤 |
| US20080102054A1 (en) | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| CA2605253C (en) | 2005-04-11 | 2017-06-13 | Yale University | Selective modulation of tumour necrosis factor receptors in therapy |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| EP1996931B1 (en) | 2005-12-28 | 2013-11-27 | The General Hospital Corporation | Blood cell sorting methods and systems |
| JP2010525049A (ja) * | 2007-04-24 | 2010-07-22 | ダイアミド セラピューティクス アーベー | 自己免疫疾患及び癌を治療する薬剤及び方法 |
| JP2009014626A (ja) * | 2007-07-06 | 2009-01-22 | Medibic:Kk | Ｂｃｇによる治療効果の予測方法 |
| EP2300614B1 (en) | 2008-02-04 | 2015-10-28 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods and compositions for treatment of mitochondrial disorders |
| US20090257982A1 (en) | 2008-04-11 | 2009-10-15 | Scheiber Lane Bernard | medical device for treating diabetes mellitus, obesity, chronic fatigue, aging, and other medical conditions by utilizing modified virus virions to insert messenger ribonucleic acid molecules into cells |
| EP2306959A2 (en) | 2008-07-11 | 2011-04-13 | The General Hospital Corporation | Magnetic apparatus for blood separation |
| EP2341934A4 (en) * | 2008-09-30 | 2012-07-25 | Baylor Res Inst | PROCESS FOR REDUCING T-HELPER CELLS FOR TREATING AUTOIMMUNE DISEASES |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| EP2192197A1 (en) * | 2008-11-27 | 2010-06-02 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist |
| US20100151062A1 (en) | 2008-12-16 | 2010-06-17 | Bruno Stefanon | Determining nutrients for animals through gene expression |
| JP5822822B2 (ja) | 2009-04-17 | 2015-11-24 | ニューヨーク ユニバーシティ | Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用 |
| KR20120005460A (ko) | 2009-04-28 | 2012-01-16 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｐｋｃ-세타 억제제를 사용하는 면역학적 장애의 생체외 치료 |
| EP2451969A2 (en) * | 2009-07-07 | 2012-05-16 | University Of Southern California | Biomarkers for the early detection of autoimmune diseases |
| EP2292260A1 (en) | 2009-08-13 | 2011-03-09 | Institut Pasteur | Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis |
| EP2470906A4 (en) * | 2009-08-24 | 2013-10-02 | Univ Columbia | ASSAY FOR DETERMINING THE HEALTH OF CD8 + T-CELLS |
| JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| CN103119054B (zh) * | 2010-03-26 | 2017-01-18 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
| US20130115207A1 (en) | 2010-04-09 | 2013-05-09 | The General Hospital Corporation | Methods for the treatment of autoimmune diseases |
| EP2585828A4 (en) | 2010-06-25 | 2014-03-12 | Glaxo Group Ltd | METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES |
| BR112013003169B1 (pt) | 2010-08-18 | 2022-05-24 | Theresa Deisher | Uso de um agente terapêutico que inibe a ligação de células-tronco a tecido linfóide |
| JP2012108112A (ja) | 2010-10-27 | 2012-06-07 | Arkray Inc | ＨｂＡ１ｃ測定結果の表示方法、表示装置、及び表示プログラム |
| WO2012122464A1 (en) | 2011-03-10 | 2012-09-13 | New York University | Methods and compositions for modulating tnf/tnfr signaling |
| WO2012174522A1 (en) | 2011-06-16 | 2012-12-20 | Children's Medical Center Corporation | Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment |
| WO2013086436A1 (en) | 2011-12-08 | 2013-06-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| WO2013131083A1 (en) | 2012-03-02 | 2013-09-06 | Winthrop-University Hospital | METHOD FOR USING PROBE BASED PCR DETECTION TO MEASURE THE LEVELS OF CIRCULATING DEMETHYLATED β CELL DERIVED DNA AS A MEASURE OF β CELL LOSS IN DIABETES |
| JP5900044B2 (ja) | 2012-03-12 | 2016-04-06 | オムロンヘルスケア株式会社 | 糖尿病治療支援装置、糖尿病治療支援方法、糖尿病治療支援プログラム |
| WO2014075098A1 (en) | 2012-11-09 | 2014-05-15 | The General Hospital Corporation | Methods and kits for diagnosing sjögren's syndrome |
| JP6367836B2 (ja) | 2013-02-07 | 2018-08-01 | ザ ジェネラル ホスピタル コーポレイション | Ｔ制御性細胞の増殖または枯渇方法 |
| EP3410115A1 (en) | 2013-05-14 | 2018-12-05 | Metabolon, Inc. | Tryptophan as a biomarkers for kidney function and methods using the same |
| WO2015057968A2 (en) | 2013-10-17 | 2015-04-23 | The General Hospital Corporation | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same |
| WO2017059132A1 (en) | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
-
2014
- 2014-10-16 WO PCT/US2014/060908 patent/WO2015057968A2/en not_active Ceased
- 2014-10-16 CN CN202010079354.5A patent/CN111239415B/zh active Active
- 2014-10-16 US US15/027,757 patent/US12174188B2/en active Active
- 2014-10-16 CN CN201480068827.4A patent/CN105829885B/zh active Active
- 2014-10-16 CN CN202010769898.4A patent/CN111879948A/zh active Pending
- 2014-10-16 JP JP2016523296A patent/JP6560200B2/ja active Active
- 2014-10-16 KR KR1020167011472A patent/KR102393711B1/ko active Active
-
2019
- 2019-07-18 JP JP2019132484A patent/JP6964632B2/ja active Active
-
2023
- 2023-10-03 JP JP2023171996A patent/JP2024001123A/ja active Pending
-
2024
- 2024-12-12 US US18/978,388 patent/US20250110122A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lim et al. | The principles of engineering immune cells to treat cancer | |
| Amarante-Mendes et al. | Therapeutic applications of TRAIL receptor agonists in cancer and beyond | |
| FI3250610T3 (fi) | Fcrn-vasta-aineita ja menetelmiä niiden käyttämiseksi | |
| PH12020500670A1 (en) | Molecular adjuvant | |
| WO2018209324A3 (en) | Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof | |
| JP2015521607A5 (enExample) | ||
| MX2014013092A (es) | Variantes de antigeno 4 del linfocito t citotoxico (ctla-4). | |
| HRP20140789T1 (hr) | Postupci primjene protutijela protiv il-5 | |
| PH12015502547A1 (en) | Anti-glucagon receptor antibodies and methods of use thereof | |
| MX2025000037A (es) | Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre | |
| WO2015057968A3 (en) | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same | |
| BR112014001516A2 (pt) | peptídeos e proteínas do vírus polioma jc nas aplicações de vacinação e de diagnóstico | |
| Yoon et al. | Adequate intensity of warfarin therapy for Korean patients with mechanical cardiac valves | |
| McFarlane et al. | A novel sickling hemoglobinopathy | |
| RU156805U1 (ru) | Туристический столик | |
| Zhao | Local or national: The research on the transformation of Chorography museum in the early period of New China | |
| Phieler et al. | C5aR contributes to adipose tissue inflammation and insulin resistance | |
| Rosen et al. | Hepatitis C virus-autoimmune hepatitis overlap syndrome in an adolescent | |
| Marie | Sonless | |
| Higurashi et al. | Kinematic gait parameters of terrestrial and arboreal locomotion in Japanese macaques | |
| RU2024102381A (ru) | Антагонист cd40l и пути его применения | |
| Yuan | Back to Square One | |
| 山本周平 | Systematic study of Staphylinoidea (Coleoptera: Staphyliniformia), with special reference to the tachyporine group subfamilies (Staphylinidae) | |
| Mohammadi et al. | Prevalence of overweight and obesity in kidney transplant patients | |
| Li et al. | C5a/C5aR signaling is an important negative regulator of murine nature killer cell homeostasis and effector function |